# Camp4 Therapeutics Corp: overview

CAMP · Nasdaq · CIK 1736730 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/camp.md) · [Financials](/companies/camp/financials.md) · [Filings](/companies/camp/filings.md) · [Insiders](/companies/camp/insiders.md)

Latest reported revenue: [$1.8m](/filings/0001628280-26-056760.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001628280-26-056760).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001736730-25-000094.md) | [0.7 d](/filings/0001736730-26-000016.md) | [0.9](/filings/0001736730-25-000039.md) | [1.5](/filings/0001736730-25-000070.md) | [0.8](/filings/0001736730-25-000094.md) | [0.3 d](/filings/0001736730-26-000016.md) | [1.3](/filings/0001628280-26-032146.md) | [1.8](/filings/0001628280-26-056760.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [(2152.5%) d](/filings/0001736730-26-000016.md) | [(1526.8%)](/filings/0001628280-26-032146.md) | [(870.3%)](/filings/0001628280-26-056760.md) | [(1717.1%)](/filings/0001736730-25-000094.md) | [(3671.3%) d](/filings/0001736730-26-000016.md) | [(1010.1%)](/filings/0001628280-26-032146.md) | [(752.1%)](/filings/0001628280-26-056760.md) |
| Net margin | % | not reported | [(2036.7%) d](/filings/0001736730-26-000016.md) | [(1449.1%)](/filings/0001628280-26-056760.md) | [(840.8%)](/filings/0001628280-26-056760.md) | [(1899.2%)](/filings/0001736730-25-000094.md) | [(11575.9%) d](/filings/0001736730-26-000016.md) | [(1416.6%)](/filings/0001628280-26-056760.md) | [(1884.8%)](/filings/0001628280-26-056760.md) |
| Diluted EPS | $ per share | [(24.19)](/filings/0001736730-25-000094.md) | not reported | [(0.62)](/filings/0001628280-26-032146.md) | [(0.62)](/filings/0001628280-26-056760.md) | [(0.55)](/filings/0001736730-25-000094.md) | not reported | [(0.32)](/filings/0001628280-26-032146.md) | [(0.58)](/filings/0001628280-26-056760.md) |
| Free cash flow | $m | [(9.7) d](/filings/0001736730-25-000094.md) | [(11.6) d](/filings/0001736730-26-000016.md) | [(14.6)](/filings/0001628280-26-032146.md) | [(10.3) d](/filings/0001628280-26-056760.md) | [(11.2) d](/filings/0001736730-25-000094.md) | [6.3 d](/filings/0001736730-26-000016.md) | [(11.0)](/filings/0001628280-26-032146.md) | [(12.8) d](/filings/0001628280-26-056760.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | [0.4](/filings/0001736730-25-000022.md) | [0.7](/filings/0001736730-26-000016.md) | [3.5](/filings/0001736730-26-000016.md) |
| Gross margin | % | not reported | not reported | not reported |
| Operating margin | % | [(14822.6%)](/filings/0001736730-25-000022.md) | [(8142.3%)](/filings/0001736730-26-000016.md) | [(1502.4%)](/filings/0001736730-26-000016.md) |
| Net margin | % | [(14083.1%)](/filings/0001736730-25-000022.md) | [(7943.4%)](/filings/0001736730-26-000016.md) | [(2298.5%)](/filings/0001736730-26-000016.md) |
| Diluted EPS | $ per share | [(124.80)](/filings/0001736730-25-000022.md) | [(11.04)](/filings/0001736730-26-000016.md) | [(2.65)](/filings/0001736730-26-000016.md) |
| Free cash flow | $m | [(44.8)](/filings/0001736730-25-000022.md) | [(46.0)](/filings/0001736730-26-000016.md) | [(29.8)](/filings/0001736730-26-000016.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/camp/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $27.9m | 6,307,636 |  | Not compared |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $27.6m | 6,307,636 |  | Not compared |
| [5AM Venture Management, LLC](/funds/1799883.md) | 2026-06-30 | $25.6m | 5,869,091 |  | Unchanged |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $21.4m | 4,904,339 |  | Reduced −29,093 |
| [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $18.6m | 4,246,568 |  | Unchanged |
| [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $11.3m | 2,575,724 |  | Reduced −56,713 |
| [a16z Capital Management, L.L.C.](/funds/1540358.md) | 2026-06-30 | $9.3m | 2,125,339 |  | Unchanged |
| [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $8.6m | 1,960,784 |  | Unchanged |
| [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $8.4m | 1,932,937 |  | Reduced −6,626 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $7.2m | 1,644,134 |  | Added +1,187,763 |

## Recent filings

[All 189 filings](/companies/camp/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-28 | 16:47 ET | [8-K](/filings/0001628280-26-063740.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-063740 |
| 2026-08-31 | 17:06 ET | [SCHEDULE 13D/A](/filings/0001753037-26-000007.md) | Ownership report, active investor, amended | 0001753037-26-000007 |
| 2026-08-19 | 19:03 ET | [SCHEDULE 13D/A](/filings/0001193125-26-357272.md) | Ownership report, active investor, amended | 0001193125-26-357272 |
| 2026-08-13 | 16:23 ET | [10-Q](/filings/0001628280-26-056760.md) | Quarterly report, period 2026-06-30 | 0001628280-26-056760 |
| 2026-08-13 | 16:22 ET | [8-K](/filings/0001628280-26-056758.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-056758 |
| 2026-08-05 | 17:43 ET | [SCHEDULE 13D/A](/filings/0001753037-26-000003.md) | Ownership report, active investor, amended | 0001753037-26-000003 |
| 2026-08-04 | 07:10 ET | [8-K](/filings/0001628280-26-052150.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-052150 |
| 2026-07-27 | 07:01 ET | [8-K](/filings/0001628280-26-049661.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-049661 |
| 2026-06-12 | 16:10 ET | [8-K](/filings/0001628280-26-042846.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001628280-26-042846 |
| 2026-05-14 | 09:01 ET | [8-K](/filings/0001736730-26-000033.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001736730-26-000033 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001736730-26-000016.md), filed Mar 5, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b582b425-b347-4a26-9e0d-6adf95350296)

## About the filer

- CIK: 1736730
- Tickers: CAMP
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.